Milliman posted Clearing hurdles for biosimilars may reduce prescription drug costs Milliman Yardley, PA:

Clearing hurdles for biosimilars may reduce prescription drug costs

There are many expensive and innovative drugs in the pipeline and there is pressure from payers, legislators, and the Trump administration to lower drug prices. Biosimilars are one option to contain increasing pharmacy costs. Biosimilars have been in the global market since 2006, but they have been slow to enter the U.S. market. As of July 2018, the U.S. has seen only four biosimilars launched under…

QR Code
Embed the QR code on your website:
Download
Copy